



Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice

Karin Sandoval¹ · David Umbaugh¹ · Austin House¹ · Albert Crider¹ · Ken Witt¹

Received: 14 June 2019 / Revised: 6 September 2019 / Accepted: 3 October 2019 / Published online: 19 October 2019
© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in memory and cognitive impairment. The use of somatostatin receptor subtype-4 (SSTR₄) agonists have been proposed for AD treatment. This study investigated the effects of selective SSTR₄ agonist NNC 26-9100 on mRNA expression of key genes associated with AD pathology (microglia mediators of A β phagocytosis, amyloid-beta (A β)-degrading enzymes, anti-oxidant enzymes and pro-inflammatory cytokines) in 3xTg-AD mice. Mice were administered NNC 26-9100 (0.2 μ g, i.c.v.) or vehicle control, with cortical and subcortical brain tissue collected at 6 h and 24 h post-treatment. At 6 h, NNC 26-9100 treatment decreased cortical expression of *cluster of differentiation-33 (Cd33)* by 25%, while increasing cortical and subcortical *macrophage scavenger receptor-1 (Msr1)* by 1.8 and 2.0-fold, respectively. The *Cd33* downregulation and *Msr1* upregulation support a state of microglia associated A β phagocytosis. At 24 h, NNC 26-9100 treatment increased the cortical expression of *Sstr4* (4.9-fold), A β -degrading enzymes *neprilysin* (9.3-fold) and *insulin degrading enzyme* (14.8-fold), and the antioxidant *catalase* (3.6-fold). Similar effects at 24 h were found in subcortical tissue with NNC 26-9100 treatment, but did not reach statistical significance. No changes in pro-inflammatory cytokine expression were found. These data demonstrated NNC 26-9100 facilitates transcriptional changes in brain tissue identified with A β phagocytosis and clearance, further supporting SSTR₄ as a treatment target for AD.

Keywords Alzheimer's disease · Somatostatin receptor subtype-4 · Microglia · Neprilysin · Insulin degrading enzyme · Cluster of differentiation 33 · Macrophage scavenger receptor-1 · Catalase · 3xTg mice

Introduction

Alzheimer's disease (AD) is the most common form of dementia. There are 30–35 million people globally currently living with AD, with a projected increase to 152 million by 2050 [1]. AD is clinically characterized by impairment in multiple cognitive domains, including memory, visuospatial skills, language, and executive function. These impairments result from destruction of the brain's neuronal networks, with amyloid-beta peptide (A β), hyperphosphorylated tau, inflammation, and oxidative stress being key contributors to the pathological process [2–4].

Substantial evidence identifies somatostatin (somatotropin release-inhibiting factor, SRIF) as a major regulator of memory and cognition [5, 6]. An extensive network of SRIF-immunoreactive neuronal fibers exist throughout the central nervous system (CNS). Within the human brain, SRIF-immunoreactivity has been shown in the neocortex, median eminence, amygdala, preoptic area, hippocampus, olfactory regions, mediobasal hypothalamus, and brain stem [6]. These regions are significantly impacted AD, with loss of SRIF neurons representing a pathological feature of AD. SRIF levels were first shown to decrease in the neocortex and hippocampus of AD patients almost four decades ago [7]. Early loss of SRIF-immunoreactive neurons and SRIF mRNA from the hippocampus in AD mouse models supports the assertion that AD pathogenesis involves SRIF mediated processes [8]. Additionally, SRIF is a known regulator of brain neprilysin (NEP) [9], an A β -degrading enzyme (A β DE) that regulates A β levels in the brain [10]. SRIF deficiency has shown to decrease hippocampal NEP activity, increasing A β ₄₂ in a

✉ Ken Witt
kwitt@siue.edu

¹ Department of Pharmaceutical Sciences Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, 200 University Park Drive., Building 220, Edwardsville, IL 62025, USA

manner similar to presenilin gene mutations observed with familial AD [9]. Given the significant involvement of SRIF in cognitive function and A β -degradation, brain localized SRIF receptors (SSTRs) may be ideal targets for the treatment of AD.

Five distinct SSTRs have been found in humans, all defined as G-protein-coupled receptors shown to be negatively coupled to pertussis-toxin sensitive pathways such as adenylyl cyclase. Of the five, the subtype-4 (SSTR₄) shows the greatest promise for AD treatment targeting [11]. SSTR₄ has optimal brain localization, being highly expressed in neurons of the neocortex, hippocampus, and olfactory bulb [12]. SSTR₄ also has limited peripheral and pituitary expression [13], reducing potential side-effects. SSTR₄ brain distribution correlates well between human and rodent, with considerable consistency between mRNA and immunoreactivity determinations [14–17]. Models of cognitive performance and pathological mitigation support SSTR₄ regulated cognitive enhancement and disease-modifying capability. We have previously shown administration of selective SSTR₄ agonist NNC 26-9100 increased spatial and recognition memory in Senescence Accelerated Mouse-Prone 8 (SAMP8) and APP^{swe} mouse models of AD [18, 19]. Correspondingly, NNC 26-9100 decreased protein expression levels of toxic A β ₄₀ and A β ₄₂ oligomers through a phosphoramidon-sensitive metalloprotease-dependent mechanism, with increased cortical NEP activity [18, 19]. Microglia also express SSTR₄ [20], with SRIF shown to enhance microglia phagocytosis and metabolism of A β [20, 21]. SSTR₄ directed microglia actions may provide another route by which to mitigate AD pathology. While such SSTR₄ agonist actions identify viability towards AD treatment, there remains a lack of understanding as to gene expression changes that may be involved.

Herein we evaluated the effects NNC 26-9100 on mRNA expression of high impact genes associated with AD and SSTR₄ in brain tissue of 10-month old 3xTg-AD mice. NNC 26-9100 is an enzymatically stable non-peptide SSTR₄ agonist (K_i = 6 nM), having > 100-fold selectivity for SSTR₄ compared to other SRIF receptor subtypes [22]. The 3xTg-AD mice contain three mutations associated with familial AD (APP Swedish, MAPT P301L, and PSEN1 M146 V). These mice display age-dependent cognitive decline, immunoreactive microglia, and accumulation of A β [23, 24]. Dose and route of NNC 26-9100 used for these evaluations have previously shown to enhance learning and memory, decrease A β ₄₀ and A β ₄₂ oligomer expression, and increase NEP activity in mouse models of AD [18, 19].

Materials and Methods

Animals, Dosing, and Dissection

3xTg-AD mice (Jackson Labs, Bar Harbor, ME) originated from the laboratory of Dr. LaFerla (University of California, Irvine, CA). Mice were housed in rooms with a 12 h light/dark cycle (20–22 °C) with water and food available ad libitum. Experimental protocols were approved by the Institutional Animal Care and Use Committee, Southern Illinois University Edwardsville, and adhere to the NIH Guide for Care and Use of Laboratory Animals. Full effort was given to minimize the animal numbers and potential suffering. At 10-months of age, mice were randomized into 6 h and 24 h, vehicle and NNC 26-9100 treatment groups (n = 5/group). This age of 3xTg-AD mice have shown increased intracellular and extracellular A β deposition in neocortex and hippocampus [24, 25]. The 24 h time-point was chosen to align with our previous research showing functional effects in mouse models of AD at this time-point following i.c.v. administration at identical dose of NNC 26-9100 used herein [18, 19]. The 6 h time point captures earlier changes in mRNA expression that may be otherwise reset by 24 h. Mice were anesthetized with isoflurane, and a unilateral hole was drilled 0.5 mm posterior and 1.0 mm to the right of the bregma. A 2 μ L intracerebroventricular injection of NNC 26-9100 (0.2 μ g) or vehicle (20% ethanol/saline) was administered to a depth of 2 mm.

At respective time-points, mice were anesthetized and perfused with 10 mL cold 0.9% NaCl saline via cardiac puncture. Brains were excised and saline washed. Pineal gland, olfactory bulbs, pituitary gland and surface vessels were removed. Cerebellum was excised, along with tissue caudal to midbrain. The corpus callosum was used to demarcate cortical and subcortical tissues. The “subcortical” tissue included the hippocampus (archicortex), caudate putamen, thalamus, globus pallidus, basal forebrain, hypothalamus, amygdala, striatum, and midbrain. The “cortical” tissue included the neocortex and the piriform cortex. The fractions were homogenized and stored in RNeasy lysis buffer (Qiagen, Crawfordsville, IN) at –20 °C until use. Unless otherwise stated all chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

RNA Isolation and cDNA Synthesis

Thawed samples were spun at 4000 \times g for 1 min, RNeasy lysis buffer supernatant was removed, Trizol RNA isolation reagent (Life Technologies, Grand Island, NY) was added (100 mg/1 mL). Following 200 μ L of 100% chloroform

and mixing, samples were centrifuged at 4 °C for 15 min at 12,000×g. The upper phase was treated with 500 µL 100% isopropanol and centrifuged 4 °C for 10 min at 12,000×g. The RNA pellet was washed with 1 mL of 75% ethanol, centrifuged at 4 °C for 5 min at 8000×g and resuspended in 60 µL RNase-free water. Samples were mixed and incubated on heating block for 5 min at 55 °C. Total RNA and purity of samples were quantified via NanoDrop-1000 (ThermoFisher). RNA underwent DNase treatment via Turbo DNase-free kit (ThermoFisher) and was incubated at 37 °C for 25 min, followed by DNase inactivation reagent to remove divalent cations. Reverse transcription of RNA to cDNA was performed via High Capacity Reverse Transcriptase kit (ThermoFisher) per manufacturers instructions, using equal volumes of RNA, 2x reverse transcriptase, and random primers reaction mix at a final volume of 20 µL and run in the following sequence: 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min. Following reverse transcription, samples were stored at –20 °C until use.

Reverse Transcription Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR)

Reactions were carried out using PowerUp SYBR Green Master Mix (ThermoFisher) using a QuantStudio3 system (ThermoFisher). All mouse primers (Table 1) were obtained from Integrated DNA Technologies (Coralville, IA). The genes investigated include: SRIF (*Sst*), SSTR 1–5 (*Sstr1*; *Sstr2*; *Sstr3*; *Sstr4*; *Sstr5*), AβDEs (neprilysin: *Nep1*; endothelin converting enzyme-1: *Ece1*; insulin degrading enzyme: *Ide*; angiotensin converting enzyme: *Ace*), inflammatory cytokines (interleukin-1β: *Il-1β*; interleukin-6: *Il-6*; tumor necrosis factor-α: *Tnf-α*; granulocyte–macrophage colony-stimulating factor: *Csf2*), microglia mediators of Aβ clearance (cluster of differentiation 68: *Cd68*; cluster of differentiation 33: *Cd33*; triggering receptor expressed on myeloid cells-2: *Trem2*; cluster of differentiation 36: *Cd36*; macrophage scavenger receptor-1: *Msr1*), and anti-oxidant enzymes (superoxide dismutase: *Sod1*; catalase: *Cat*), with Cytochrome C1 (*Cyc1*) as reference gene. *Cyc1* was chosen as reference given its stability in brain tissue respective to neurodegenerative disease [26], with stability confirmed in our run-up evaluations.

Samples were run in triplicate, with 10 µL of Master Mix, 200–500 nM primer, 8 µL dH₂O, and 2 µL cDNA. A

Table 1 Genes and corresponding primer pair information

Gene	Accession no.	Primer sequence (5'–3')	Bp
<i>Cyc1</i> *	NM_025567	Sense: anti-sense CACAGTAGCCAGTGAGCAG CAAAACCATACCCTAACCCCT	133
<i>Sst</i>	NM_009215	Sense: anti-sense GGCATCATTCTCTGTCTGGTT AGACTCCGTCAGTTTCTGC	114
<i>Sstr1</i>	NM_009216	Sense: anti-sense AAGGCTCTGGACTGATGAATG CAGGTTTAAAGAACTGGCAAGC	82
<i>Sstr2</i>	NM_009217	Sense: anti-sense GAAGATGAAGACAGCCACTACG TTGTCTCTGCTACCTGTTCATC	130
<i>Sstr3</i>	NM_009218	Sense: anti-sense GAGATGAGGATCAGTCAGCAG AAACCAGACGCAAGCTACC	142
<i>Sstr4</i>	NM_009219	Sense: anti-sense GGTGGCTGTCTTCATCTTGG ATCTATGCGCTCGTGTGTGTC	90
<i>Sstr5</i>	NM_011425	Sense: anti-sense TGAGGCATTCCAGCTAGGT TTCCACCTACTGAGCTCCA	129
<i>Nep1</i>	NM_008604	Sense: anti-sense CACAGCATTCTCCATATTCCCA GCCTCAGCCGAAACTACAAG	109
<i>Ece1</i>	NM_199307	Sense: anti-sense TGAGTCCACCAGATCCTCTT TTACCACTACTTCCACAAGCTG	102
<i>Ide</i>	NM_031156	Sense: anti-sense CTTCTACTCTGCTCTCCAGGTA TTGGCTATATTGTCTTCAGTGGA	108
<i>Ace</i>	NM_009598	Sense: anti-sense TTCACAGAGGTACTGCTTG ACAAGTCGATGTTAGAGAAGCC	112
<i>Il-1β</i>	NM_008361	Sense: anti-sense GACCTGTCTTTGAAGTTGACG CTCTTGTGTGATGTGCTGCTG	119
<i>Il-6</i>	NM_031168	Sense: anti-sense TCCTTAGCCACTCCTTCTGT AGCCAGAGTCCTTCAGAGA	146
<i>Tnf-α</i>	NM_013693	Sense: anti-sense AGACCCTCACACTCAGATCA TCTTTGAGATCCATGCCGTTG	145
<i>Csf2</i>	NM_009969	Sense: anti-sense CCTTGAGTTTGGTGAATTGCC GTCTCTAACGAGTTCTCCTTCA	97
<i>Cd68</i>	NM_009853	Sense: anti-sense TCAGGGTGAAGAAAGGTAAG CCATAAGGAAATGAGAGAGACAGG	138
<i>Cd33</i>	NM_021293	Sense: anti-sense TGCAGAACATCACAATGAGAAAC GAAAGGACCATCCAGCTCAA	136
<i>Trem2</i>	NM_001272078	Sense: anti-sense GCTTCAAGGCGTCATAAGTACA GACCTCTCCACCAGTTTCTC	123
<i>Cd36</i>	NM_001159558	Sense: anti-sense CAGTTGCTCCACATTTTCAG TCTCCTTCAACAGTCTCCCT	100
<i>Msr1</i>	NM_031195	Sense: anti-sense CACAAGGAGGTAGAGAGCAATG GCACGTTCAATGACAGCATC	108
<i>Sod1</i>	NM_011434	Sense: anti-sense GTCCTTTCAGCAGTCACAT GGTTCCACGTCATCAGTATG	146
<i>Cat</i>	NM_009804	Sense: anti-sense ATCTTCTGAGCAAGCCTTC CAAGTTGGTTAATGCAGATGGA	112

Bp length of the amplicon in base pair. *Cyc1** served as reference gene [26]

Table 2 Cortical 6 h mRNA expression

Gene	Vehicle 6-hr	Treated 6-hr	P value
<i>Somatostatin and somatostatin receptors</i>			
<i>Sst</i>			
$\Delta\Delta Ct$	0.000 ± 0.314	-0.654 ± 0.379	P = 0.2207
$2^{(-\Delta\Delta Ct)}$	1.000 (0.546–1.831)	1.574 (0.759–3.265)	
<i>Sstr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.101	-0.229 ± 0.089	P = 0.1265
$2^{(-\Delta\Delta Ct)}$	1.000 (0.824–1.214)	1.172 (0.988–1.389)	
<i>Sstr2</i>			
$\Delta\Delta Ct$	0.000 ± 0.283	0.514 ± 0.108	P = 0.1281
$2^{(-\Delta\Delta Ct)}$	1.000 (0.580–1.723)	0.700 (0.569–0.863)	
<i>Sstr3</i>			
$\Delta\Delta Ct$	0.000 ± 0.168	-0.029 ± 0.064	P = 0.8767
$2^{(-\Delta\Delta Ct)}$	1.000 (0.723–1.383)	1.020 (0.902–1.154)	
<i>Sstr4</i>			
$\Delta\Delta Ct$	0.000 ± 0.810	0.077 ± 0.309	P = 0.9317
$2^{(-\Delta\Delta Ct)}$	1.000 (0.211–4.749)	0.948 (0.523–1.718)	
<i>Sstr5</i>			
$\Delta\Delta Ct$	0.000 ± 0.290	1.026 ± 0.395	P = 0.0695
$2^{(-\Delta\Delta Ct)}$	1.000 (0.572–1.748)	0.491 (0.230–1.049)	
<i>Aβ-degrading enzymes</i>			
<i>Nep1</i>			
$\Delta\Delta Ct$	0.000 ± 1.265	0.325 ± 0.162	P = 0.8108
$2^{(-\Delta\Delta Ct)}$	1.000 (0.088–11.405)	0.798 (0.585–1.089)	
<i>Ece1</i>			
$\Delta\Delta Ct$	0.000 ± 1.100	0.718 ± 0.370	P = 1.000 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.120–8.311)	0.608 (0.298–1.238)	
<i>Ide</i>			
$\Delta\Delta Ct$	0.000 ± 0.978	-0.085 ± 0.446	P = 0.9392
$2^{(-\Delta\Delta Ct)}$	1.000 (0.152–6.566)	1.060 (0.449–2.503)	
<i>Ace</i>			
$\Delta\Delta Ct$	0.000 ± 0.464	-0.517 ± 0.434	P = 0.4392
$2^{(-\Delta\Delta Ct)}$	1.000 (0.409–2.445)	1.431 (0.621–3.297)	
<i>Inflammatory cytokines</i>			
<i>IL-1β</i>			
$\Delta\Delta Ct$	0.000 ± 0.681	-0.531 ± 0.607	P = 0.5762
$2^{(-\Delta\Delta Ct)}$	1.000 (0.270–3.706)	1.445 (0.450–4.646)	
<i>IL-6</i>			
$\Delta\Delta Ct$	0.000 ± 0.715	-0.929 ± 0.408	P = 0.3235 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.253–3.957)	1.904 (0.868–4.174)	

Table 2 (continued)

Gene	Vehicle 6-hr	Treated 6-hr	P value
<i>Tnf-α</i>			
$\Delta\Delta Ct$	0.000 ± 0.364	-0.110 ± 0.363	P = 0.8354
$2^{(-\Delta\Delta Ct)}$	1.000 (0.496–2.016)	1.080 (0.537–2.171)	
<i>Csf2</i>			
$\Delta\Delta Ct$	0.000 ± 0.364	-0.253 ± 0.560	P = 0.7144
$2^{(-\Delta\Delta Ct)}$	1.000 (0.496–2.015)	1.192 (0.406–3.503)	
<i>Microglia mediators of Aβ clearance</i>			
<i>Cd68</i>			
$\Delta\Delta Ct$	0.000 ± 0.169	0.324 ± 0.104	P = 0.1412
$2^{(-\Delta\Delta Ct)}$	1.000 (0.722–1.385)	0.799 (0.654–0.976)	
<i>Cd33</i>			
$\Delta\Delta Ct$	0.000 ± 0.099	0.420 ± 0.136	* P = 0.0369
$2^{(-\Delta\Delta Ct)}$	1.000 (0.827–1.209)	0.747 (0.575–0.971)	
<i>Trem2</i>			
$\Delta\Delta Ct$	0.000 ± 0.329	-0.015 ± 0.104	P = 0.4250 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.531–1.884)	1.011 (0.827–1.235)	
<i>Cd36</i>			
$\Delta\Delta Ct$	0.000 ± 0.200	-0.378 ± 0.370	P = 0.3949
$2^{(-\Delta\Delta Ct)}$	1.000 (0.680–1.470)	1.300 (0.638–2.648)	
<i>Msr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.301	-0.872 ± 0.166	* P = 0.0347
$2^{(-\Delta\Delta Ct)}$	1.000 (0.561–1.784)	1.830 (1.331–2.518)	
<i>Anti-oxidants</i>			
<i>Sod1</i>			
$\Delta\Delta Ct$	0.000 ± 0.081	0.054 ± 0.030	P = 0.5507
$2^{(-\Delta\Delta Ct)}$	1.000 (0.856–1.168)	0.964 (0.909–1.021)	
<i>Cat</i>			
$\Delta\Delta Ct$	0.000 ± 0.468	-0.243 ± 0.332	P = 0.6823
$2^{(-\Delta\Delta Ct)}$	1.000 (0.407–2.459)	1.184 (0.625–2.242)	

Data shown as mean $\Delta\Delta Ct \pm SEM$, with *t* test used to identify the difference between vehicle and NNC 26-9100 treatment groups, significance set at **P* < 0.05. Fold difference relative to vehicle shown as $2^{(-\Delta\Delta Ct)}$ with 95% confidence interval

^{np}Denotes use of Wilcoxon rank sum test

negative water control was included in each run. The reaction sequence was 50 °C for 2 min, 95 °C for 2 min, followed by 45 cycles at 95 °C for 15 s and then 60 °C for 1 min. Melt curves were performed to verify the absence of primer-dimer formation: 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s. No Cq values exceeded 36. Relative mRNA expression for each target was calculated using the $2^{(-\Delta\Delta Ct)}$ method [27].

Table 3 Subcortical 6 h mRNA expression

Gene	Vehicle 6-h	Treated 6-h	P-value
<i>Somatostatin and somatostatin receptors</i>			
<i>Sst</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.616	0.498 ± 0.459	P = 0.5346
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.306–3.271)	0.708 (0.293–1.711)	
<i>Sstr1</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.101	-0.006 ± 0.130	P = 0.9713
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.823–1.215)	1.004 (0.782–1.289)	
<i>Sstr2</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.184	0.157 ± 0.188	P = 0.5666
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.702–1.424)	0.897 (0.625–1.287)	
<i>Sstr3</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.178	0.242 ± 0.133	P = 0.3076
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.710–1.409)	0.846 (0.655–1.092)	
<i>Sstr4</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.622	0.275 ± 0.436	P = 0.7267
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.302–3.311)	0.826 (0.357–1.911)	
<i>Sstr5</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.184	-0.093 ± 0.393	P = 0.8355
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.702–1.424)	1.067 (0.501–2.271)	
<i>Aβ-degrading enzymes</i>			
<i>Nep1</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.840	0.651 ± 0.497	P = 0.5233
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.199–5.035)	0.637 (0.245–1.656)	
<i>Ece1</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 1.071	0.966 ± 0.426	P = 0.8392 ^{np}
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.127–7.858)	0.512 (0.225–1.163)	
<i>Ide</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.732	0.936 ± 0.428	P = 0.3019
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.244–4.090)	0.523 (0.229–1.192)	
<i>Ace</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.945	0.504 ± 0.499	P = 0.6498
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.162–6.163)	0.705 (0.270–1.841)	
<i>Inflammatory cytokines</i>			
<i>IL-1β</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.523	0.764 ± 0.469	P = 0.3086
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.365–2.738)	0.589 (0.239–1.452)	
<i>IL-6</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.372	-1.075 ± 0.598	P = 0.1657
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.489–2.046)	2.106 (0.666–6.663)	
<i>Tnf-α</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.440	-0.817 ± 0.459	P = 0.2349
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.429–2.332)	1.761 (0.728–4.262)	
<i>Csf2</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.355	-0.842 ± 0.375	P = 0.1418
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.505–1.981)	1.793 (0.871–3.691)	
<i>Microglia mediators of Aβ clearance</i>			
<i>Cd68</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.086	-0.151 ± 0.213	P = 0.5309
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.847–1.180)	1.110 (0.736–1.674)	

Table 3 (continued)

Gene	Vehicle 6-h	Treated 6-h	P-value
<i>Cd33</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.116	0.052 ± 0.130	P = 0.7709
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.800–1.250)	0.964 (0.751–1.238)	
<i>Trem2</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.161	0.031 ± 0.157	P = 0.8953
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.733–1.364)	0.979 (0.724–1.325)	
<i>Cd36</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.149	0.106 ± 0.227	P = 0.7068
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.751–1.332)	0.929 (0.600–1.439)	
<i>Msr1</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.257	-1.019 ± 0.185	* P = 0.0124
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.609–1.641)	2.026 (1.419–2.892)	
<i>Anti-oxidants</i>			
<i>Sod1</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.038	-0.013 ± 0.034	P = 0.8042
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.930–1.076)	1.009 (0.945–1.078)	
<i>Cat</i>			
$\Delta\Delta\text{Ct}$	0.000 ± 0.837	0.934 ± 0.456	P = 0.8392 ^{np}
$2^{(-\Delta\Delta\text{Ct})}$	1.000 (0.200–5.011)	0.523 (0.218–1.259)	

Data shown as mean $\Delta\Delta\text{Ct} \pm \text{SEM}$, with *t* test used to identify the difference between vehicle and NNC 26-9100 treatment groups, significance set at **P* < 0.05. Fold difference relative to vehicle shown as $2^{(-\Delta\Delta\text{Ct})}$ with 95% confidence interval

^{np}Denotes use of Wilcoxon rank sum test

Statistical Analyses

The dependent variable assessed was the $\Delta\Delta\text{Ct}$ [28]. The type I error was set at 0.05 for all analyses, with significance set at *P* < 0.05. Independent *t* tests conducted between vehicle and NNC 26-9100 treatment groups, respective to tissue and time-point. For *t* tests, the data was analyzed for normality of the distribution and that the variances were equal. Equality of variance assessed using a folded F-test. If the variance was not equal between groups, the Satterthwaite approximation was used. If the distribution was non-normal, the Wilcoxon rank sum test was used. 95% confidence intervals constructed for the $2^{(-\Delta\Delta\text{Ct})}$ fold-change determinations. Analyses performed using SAS v9.4 (SAS Institute Inc., Cary, NC).

Results

Cortical 6 h mRNA Expression

NNC 26-9100 treatment examined in cortical tissue at 6 h (Table 2). The mean $\Delta\Delta\text{Ct}$ for *Cd33* significantly increased with NNC 26-9100 treatment, corresponding to a 25% decrease in mRNA expression. The mean $\Delta\Delta\text{Ct}$ for *Msr1* significantly decreased with NNC 26-9100 treatment,

Table 4 Cortical 24 h mRNA expression

Gene	Vehicle 24-h	Treated 24-h	P-value
<i>Somatostatin and somatostatin receptors</i>			
<i>Sst</i>			
$\Delta\Delta Ct$	0.000 ± 1.385	-2.164 ± 1.015	P = 0.1777 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.070–14.382)	4.483 (0.636–31.595)	
<i>Sstr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.070	-0.141 ± 0.192	P = 0.5109
$2^{(-\Delta\Delta Ct)}$	1.000 (0.874–1.144)	1.102 (0.762–1.595)	
<i>Sstr2</i>			
$\Delta\Delta Ct$	0.000 ± 0.110	0.180 ± 0.187	P = 0.4316
$2^{(-\Delta\Delta Ct)}$	1.000 (0.810–1.235)	0.883 (0.616–1.266)	
<i>Sstr3</i>			
$\Delta\Delta Ct$	0.000 ± 0.150	-0.109 ± 0.209	P = 0.6838
$2^{(-\Delta\Delta Ct)}$	1.000 (0.750–1.334)	1.078 (0.721–1.612)	
<i>Sstr4</i>			
$\Delta\Delta Ct$	0.000 ± 0.712	-2.299 ± 0.480	* P = 0.0280
$2^{(-\Delta\Delta Ct)}$	1.000 (0.254–3.933)	4.920 (1.955–12.383)	
<i>Sstr5</i>			
$\Delta\Delta Ct$	0.000 ± 0.432	0.264 ± 0.313	P = 0.6338
$2^{(-\Delta\Delta Ct)}$	1.000 (0.435–2.298)	0.833 (0.456–1.521)	
<i>Aβ-degrading enzymes</i>			
<i>Nep1</i>			
$\Delta\Delta Ct$	0.000 ± 0.834	-3.217 ± 0.285	* P = 0.0065
$2^{(-\Delta\Delta Ct)}$	1.000 (0.201–4.975)	9.301 (5.375–16.096)	
<i>Ece1</i>			
$\Delta\Delta Ct$	0.000 ± 0.575	-2.426 ± 1.025	P = 0.0729
$2^{(-\Delta\Delta Ct)}$	1.000 (0.330–3.026)	5.375 (0.748–38.631)	
<i>Ide</i>			
$\Delta\Delta Ct$	0.000 ± 1.700	-3.889 ± 0.568	* P = 0.0472^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.038–26.358)	14.819 (4.964–44.234)	
<i>Ace</i>			
$\Delta\Delta Ct$	0.000 ± 1.547	-3.222 ± 0.508	P = 0.0832
$2^{(-\Delta\Delta Ct)}$	1.000 (0.051–19.636)	9.328 (3.510–24.789)	
<i>Inflammatory cytokines</i>			
<i>IL-1β</i>			
$\Delta\Delta Ct$	0.000 ± 0.352	-0.024 ± 0.514	P = 1.000 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.508–1.969)	1.017 (0.378–2.733)	
<i>IL-6</i>			
$\Delta\Delta Ct$	0.000 ± 0.510	0.064 ± 0.358	P = 1.000 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.375–2.668)	0.956 (0.480–1.907)	

Table 4 (continued)

Gene	Vehicle 24-h	Treated 24-h	P-value
<i>Tnf-a</i>			
$\Delta\Delta Ct$	0.000 ± 0.159	0.274 ± 0.586	P = 0.6717
$2^{(-\Delta\Delta Ct)}$	1.000 (0.736–1.358)	0.827 (0.268–2.552)	
<i>Csf2</i>			
$\Delta\Delta Ct$	0.000 ± 0.396	0.478 ± 0.800	P = 0.6073
$2^{(-\Delta\Delta Ct)}$	1.000 (0.466–2.144)	0.718 (0.154–3.349)	
<i>Microglia mediators of Aβ clearance</i>			
<i>Cd68</i>			
$\Delta\Delta Ct$	0.000 ± 0.155	-0.195 ± 0.155	P = 0.4004
$2^{(-\Delta\Delta Ct)}$	1.000 (0.742–1.347)	1.144 (0.849–1.543)	
<i>Cd33</i>			
$\Delta\Delta Ct$	0.000 ± 0.096	0.097 ± 0.104	P = 0.5152
$2^{(-\Delta\Delta Ct)}$	1.000 (0.831–1.204)	0.935 (0.765–1.143)	
<i>Trem2</i>			
$\Delta\Delta Ct$	0.000 ± 0.092	-0.033 ± 0.167	P = 0.8687
$2^{(-\Delta\Delta Ct)}$	1.000 (0.838–1.193)	1.023 (0.742–1.410)	
<i>Cd36</i>			
$\Delta\Delta Ct$	0.000 ± 0.410	0.549 ± 0.379	P = 0.3544
$2^{(-\Delta\Delta Ct)}$	1.000 (0.454–2.201)	0.684 (0.330–1.417)	
<i>Msr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.507	0.454 ± 0.301	P = 0.4636
$2^{(-\Delta\Delta Ct)}$	1.000 (0.377–2.653)	0.730 (0.409–1.303)	
<i>Anti-oxidants</i>			
<i>Sod1</i>			
$\Delta\Delta Ct$	0.000 ± 0.047	0.054 ± 0.064	P = 0.5183
$2^{(-\Delta\Delta Ct)}$	1.000 (0.913–1.095)	0.964 (0.853–1.089)	
<i>Cat</i>			
$\Delta\Delta Ct$	0.000 ± 0.553	-1.843 ± 0.409	* P = 0.0279
$2^{(-\Delta\Delta Ct)}$	1.000 (0.345–2.896)	3.589 (1.632–7.890)	

Data shown as mean $\Delta\Delta Ct \pm SEM$, with *t* test used to identify the difference between vehicle and NNC 26-9100 treatment groups, significance set at **P* < 0.05. Fold difference relative to vehicle shown as $2^{(-\Delta\Delta Ct)}$ with 95% confidence interval

^{np}Denotes use of Wilcoxon rank sum test

corresponding to a 1.8-fold increase in mRNA expression. No other significant differences were found.

Subcortical 6 h mRNA Expression

NNC 26-9100 treatment examined in subcortical tissue at 6 h (Table 3). The mean $\Delta\Delta Ct$ for *Msr1* significantly decreased with NNC 26-9100 treatment, corresponding to a

Table 5 Subcortical 24 h mRNA expression

Gene	Vehicle 24-h	Treated 24-h	P-value
<i>Somatostatin and somatostatin receptors</i>			
<i>Sst</i>			
$\Delta\Delta Ct$	0.000 ± 1.114	-2.150 ± 0.864	P = 0.1656
$2^{(-\Delta\Delta Ct)}$	1.000 (0.117–8.528)	4.439 (0.842–23.391)	
<i>Sstr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.082	0.110 ± 0.078	P = 0.3573
$2^{(-\Delta\Delta Ct)}$	1.000 (0.855–1.170)	0.926 (0.797–1.076)	
<i>Sstr2</i>			
$\Delta\Delta Ct$	0.000 ± 0.205	0.167 ± 0.103	P = 0.4864
$2^{(-\Delta\Delta Ct)}$	1.000 (0.674–1.483)	0.891 (0.730–1.087)	
<i>Sstr3</i>			
$\Delta\Delta Ct$	0.000 ± 0.053	0.134 ± 0.120	P = 0.3356
$2^{(-\Delta\Delta Ct)}$	1.000 (0.904–1.107)	0.911 (0.724–1.147)	
<i>Sstr4</i>			
$\Delta\Delta Ct$	0.000 ± 0.766	-1.714 ± 0.613	P = 0.1190
$2^{(-\Delta\Delta Ct)}$	1.000 (0.229–4.369)	3.280 (1.008–10.675)	
<i>Sstr5</i>			
$\Delta\Delta Ct$	0.000 ± 0.295	-0.022 ± 0.182	P = 0.9502
$2^{(-\Delta\Delta Ct)}$	1.000 (0.567–1.764)	1.016 (0.716–1.441)	
<i>Aβ-degrading enzymes</i>			
<i>Nep1</i>			
$\Delta\Delta Ct$	0.000 ± 0.894	-1.244 ± 0.687	P = 0.2980
$2^{(-\Delta\Delta Ct)}$	1.000 (0.139–7.186)	2.368 (0.631–8.884)	
<i>Ece1</i>			
$\Delta\Delta Ct$	0.000 ± 0.520	-1.124 ± 0.676	P = 0.2238
$2^{(-\Delta\Delta Ct)}$	1.000 (0.368–2.719)	2.180 (0.594–8.003)	
<i>Ide</i>			
$\Delta\Delta Ct$	0.000 ± 0.908	-1.990 ± 0.772	P = 0.1336
$2^{(-\Delta\Delta Ct)}$	1.000 (0.174–5.743)	3.973 (0.889–17.567)	
<i>Ace</i>			
$\Delta\Delta Ct$	0.000 ± 0.911	-1.898 ± 0.612	P = 0.1161
$2^{(-\Delta\Delta Ct)}$	1.000 (0.134–7.457)	3.278 (1.148–12.105)	
<i>Inflammatory cytokines</i>			
<i>IL-1β</i>			
$\Delta\Delta Ct$	0.000 ± 0.374	0.662 ± 0.299	P = 0.2038
$2^{(-\Delta\Delta Ct)}$	1.000 (0.487–2.052)	0.632 (0.335–1.124)	
<i>IL-6</i>			
$\Delta\Delta Ct$	0.000 ± 0.514	0.146 ± 0.217	P = 0.7998
$2^{(-\Delta\Delta Ct)}$	1.000 (0.372–2.689)	0.904 (0.595–1.373)	

Table 5 (continued)

Gene	Vehicle 24-h	Treated 24-h	P-value
<i>Tnf-a</i>			
$\Delta\Delta Ct$	0.000 ± 0.434	0.112 ± 0.277	P = 0.8335
$2^{(-\Delta\Delta Ct)}$	1.000 (0.434–2.304)	0.925 (0.543–1.576)	
<i>Csf2</i>			
$\Delta\Delta Ct$	0.000 ± 0.178	-0.104 ± 0.257	P = 0.7480
$2^{(-\Delta\Delta Ct)}$	1.000 (0.709–1.410)	1.075 (0.656–1.762)	
<i>Microglia mediators of Aβ clearance</i>			
<i>Cd68</i>			
$\Delta\Delta Ct$	0.000 ± 0.223	-0.403 ± 0.229	P = 0.2433
$2^{(-\Delta\Delta Ct)}$	1.000 (0.651–1.537)	1.322 (0.851–2.054)	
<i>Cd33</i>			
$\Delta\Delta Ct$	0.000 ± 0.114	-0.145 ± 0.154	P = 0.4250 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.804–1.244)	1.105 (0.822–1.486)	
<i>Trem2</i>			
$\Delta\Delta Ct$	0.000 ± 0.088	-0.262 ± 0.137	P = 0.1472
$2^{(-\Delta\Delta Ct)}$	1.000 (0.844–1.185)	1.199 (0.921–1.562)	
<i>Cd36</i>			
$\Delta\Delta Ct$	0.000 ± 0.474	0.177 ± 0.458	P = 0.8392 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.402–2.488)	0.885 (0.367–2.134)	
<i>Msr1</i>			
$\Delta\Delta Ct$	0.000 ± 0.619	0.143 ± 0.319	P = 0.8419
$2^{(-\Delta\Delta Ct)}$	1.000 (0.304–3.290)	0.905 (0.490–1.673)	
<i>Anti-oxidants</i>			
<i>Sod1</i>			
$\Delta\Delta Ct$	0.000 ± 0.071	0.026 ± 0.072	P = 0.8018
$2^{(-\Delta\Delta Ct)}$	1.000 (0.873–1.146)	0.982 (0.855–1.128)	
<i>Cat</i>			
$\Delta\Delta Ct$	0.000 ± 0.712	-1.569 ± 0.670	P = 0.1290 ^{np}
$2^{(-\Delta\Delta Ct)}$	1.000 (0.254–3.940)	2.968 (0.818–10.772)	

Data shown as mean $\Delta\Delta Ct \pm SEM$, with *t* test used to identify the difference between vehicle and NNC 26-9100 treatment groups, significance set at **P* < 0.05. Fold difference relative to vehicle shown as $2^{(-\Delta\Delta Ct)}$ with 95% confidence interval

^{np}Denotes use of Wilcoxon rank sum test

2.0-fold increase in mRNA expression. No other significant differences were found.

Cortical 24 h mRNA Expression

NNC 26-9100 treatment examined in cortical tissue at 24 h (Table 4). The mean $\Delta\Delta Ct$ for *Sstr4* and *Cat* significantly decreased with NNC 26-9100 treatment,

corresponding to a 4.9- and 3.6-fold increase in mRNA expression, respectively. The $\Delta\Delta\text{Ct}$ for both *Nep1* and *Ide* significantly decreased with NNC 26-9100 treatment, corresponding to a 9.3 and 14.8-fold increase in mRNA expression, respectively. While NNC 26-9100 treatment increased *Sst* (4.4-fold), *Ece1* (5.4-fold), and *Ace* (9.3-fold) mRNA expression, they did not reach statistical significance. No other significant differences were found.

Subcortical 24 h mRNA Expression

NNC 26-9100 treatment examined in subcortical tissue at 24 h (Table 5). While no statistically significant differences were found between NNC 26-9100 and vehicle treatment, the increases in *Sstr4* (3.3-fold), *Sst* (4.4-fold), *Nep1* (2.4-fold), *Ide* (4.4-fold), *Ece1* (2.8-fold), *Ace* (3.3-fold), and *Cat* (3.0-fold) parallel the 24 h cortical mRNA expression observations.

Discussion

Herein, we show SSTR₄ agonist NNC 26-9100 alters brain tissue mRNA expression of key AD and SRIF associated genes. Overall, cortical tissue mRNA effects were more robust than those effects observed from subcortical tissue. This effect is likely accounted for by the higher level of SSTR₄ expression in grey matter tissues [12]. The subcortical regions being more diverse in gray/white matter content. High levels of SSTR₄ are expressed throughout the neocortex, with expression decreasing progressively towards more caudal brain regions [14–17]. Moreover, the respective subcortical regions vary significantly in functionality, which may differentially effect gene translation. Nevertheless, mRNA expression changes observed with treatment identify a relatively consistent effect between cortical and subcortical tissues.

The upregulated cortical *Sstr4* mRNA expression at 24 h by NNC 26-9100 is consistent with increased receptor turnover. A similar but non-significant effect was found in subcortical tissue. This parallels CHO-K1 cell evaluations identifying SRIF-induced upregulation of human SSTR₄ [29]. While cooperative interaction between SSTR₄ and other SSTRs has been shown [30–32], no change in mRNA expression of any other SSTR with NNC 26-9100 treatment was found. This supports the observed expression changes are specific to SSTR₄.

Cortical *Nep1* and *Ide* mRNA expression were upregulated by NNC 26-9100 at 24 h, with a similar but non-significant increase observed in subcortical tissue. Each of these zinc-metalloproteases are capable of degrading A β [33, 34]. NEP is membrane associated and principally expressed in neurons [35]. NEP is capable of degrading A β monomers and synthetic oligomers [36, 37]. The observed upregulation

of *Nep1*, along with our previous data showing increased cortical NEP activity with NNC 26-9100 [18] further corroborates SSTR₄ mediated regulation of NEP in the brain. IDE is primarily cytosolic associated and expressed in neurons and glia [38, 39]. IDE has shown to clear cytoplasmic A β in human hippocampal lysates [40]. Notably, SRIF has shown to increase IDE expression and secretion from microglia, with an associated A β ₄₀ decrease [21]. Given the presence of SSTR₄ on microglia [20], the upregulation of *Ide* within our evaluation may be microglia derived.

While the effects of NNC 26-9100 on A β DE mRNA expression were consistent between cortical and subcortical homogenates, changes in subcortical tissue did not reach significance. Given NEP is primarily neuronal, it is not unexpected that *Nep1* upregulation would be greater in cortical tissue. IDE may also be impacted by the lower density of microglia in white matter compared to grey matter [41]. Nevertheless, the memory forming hippocampal neurons that were extracted within our subcortical homogenates do express NEP [10], ECE [42], IDE [40], and ACE [43], along with SSTR₄ [12].

No changes in mRNA expression were found for *IL-1 β* , *IL-6*, *Tnf- α* or *Csf2* in cortical or subcortical, at 6 h or 24 h. Other research has shown SSTR₄ agonist use capable of reducing endotoxin-induced granulocyte accumulation and IL-1 β synthesis [44]. Additionally, IL-6 and TNF- α have shown to be upregulated under inflammatory conditions in SSTR₄ knockout-mice compared to wild-type controls [45]. However, such SSTR₄ anti-inflammatory effects were only apparent under heightened inflammatory states, which were not present in our study.

No mRNA expression changes were found with NNC 26-9100 treatment for *Cd68*, *Trem2* or *Cd36*, which are associated with microglia activation, A β -binding, and phagocytosis [46]. However, NNC 26-9100 treatment decreased cortical *Cd33* expression at 6 h. *Cd33* is a cell surface protein predominantly expressed on microglia [47], which positively correlates with amyloid plaque burden [48]. Reduction of *Cd33* mRNA expression is most likely beneficial, as *Cd33* has been shown to be elevated in AD patients at both the mRNA and protein level [48]. Furthermore, APP_{Swe}/PS1 ΔE9 mice with the *Cd33* gene knocked-out show a marked decrease of insoluble A β ₄₂ and A β plaque burden [48]. Conversely, cortical and subcortical *Msr1* (a.k.a. Scara1) expression significantly increased with NNC 26-9100 treatment at 6 h. *Msr1* is a microglia receptor involved in the phagocytosis of fibrillar and soluble A β [49, 50]. When *Msr1* was knocked-out in APP_{Swe}/PS1 ΔE9 mice a marked increase in soluble A β and mortality was found [50]. Interestingly, both *Nep* and *Ide* are significantly lower in the brains of APP_{Swe}/PS1 ΔE9 *Msr1* knock-outs compared to APP_{Swe}/PS1 ΔE9 controls [50], identifying a link between microglia A β regulation and A β DEs. The *Cd33* downregulation and *Msr1* upregulation at 6 h support a state of microglia associated A β phagocytosis occurring prior to the observed A β DE upregulation at 24 h.

While cortical *Cat* expression significantly increased with treatment at 24 h, no change was observed in *Sod1* expression. The corresponding enzymes often act in concert, with superoxide dismutase converting the superoxide radical anion to hydrogen peroxide, and catalase breaking down hydrogen peroxide into water and oxygen. Reduced activity of these enzymes has been reported in AD, indicating a compromised oxidative stress defense mechanism [51]. However, variations in superoxide dismutase and catalase have also been noted in evaluations of AD brain tissues. While accumulation of hydrogen peroxide in AD brains without changes in superoxide dismutase was shown by Gsell and colleagues [52], others have shown regional increases in superoxide dismutase and catalase in AD brains [53]. Such disparity may reflect different disease stages and regional tissue effects. Catalase is also heavily associated with peroxisomes, where it has shown to reduce A β induced oxidative stress [54, 55]. Interestingly, IDE is also concentrated in peroxisomes [56], and could benefit from enhanced catalase activity. A β DE oxidation has been suggested to contribute to reduced enzymatic activity with corresponding A β deposition [57, 58]. Enhanced IDE oxidation has also been shown in the hippocampus and neocortex of AD patients [57]. As to whether *Cat* upregulation is a direct result of SSTR₄ agonist action or secondary to other processes remains to be determined.

These data demonstrated SSTR₄ agonist NNC 26-9100 facilitates transcriptional changes in the brain identified with enhanced A β phagocytosis and clearance, which aligns with our previous work [18, 19]. The 6 h *Cd33* and *Msr1* expression changes associated with microglia mediated A β phagocytosis and the 24 h upregulation of primary A β -degrading enzymes *Nep* and *Ide*, as well as the antioxidant *Cat*, identify different time frames of expressional regulation. While SSTR₄ has the capacity to activate a number of pathways that influence transcription [59], the specific signaling cascades and potential interdependency of cellular processes involved remains to be determined. This work provides mechanistic insight as to SSTR₄ agonist actions within the brain, further supporting SSTR₄ as a treatment target for AD.

Acknowledgements This work was supported the National Institutes of Health, National Institute of Age division, grant no. R01AG047858, and Southern Illinois University Edwardsville Graduate School.

References

- World Health Organisation (2019) Dementia fact sheet May 2019. <https://www.who.int/news-room/fact-sheets/detail/dementia>. Accessed July 9, 2019
- Bradburn S, Murgatroyd C, Ray N (2019) Neuroinflammation in mild cognitive impairment and Alzheimer's disease: a meta-analysis. *Ageing Res Rev* 50:1–8
- Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement* 14:535–562
- Wojsiat J, Zoltowska KM, Laskowska-Kaszub K, Wojda U (2018) Oxidant/antioxidant imbalance in Alzheimer's disease: therapeutic and diagnostic prospects. *Oxid Med Cell Longev* 2018:6435861
- Epelbaum J, Guillou JL, Gastambide F, Hoyer D, Duron E, Viollet C (2009) Somatostatin, Alzheimer's disease and cognition: An old story coming of age? *Prog Neurobiol* 89:153–161
- Martel G, Dutar P, Epelbaum J, Viollet C (2012) Somatostatinergic systems: an update on brain functions in normal and pathological aging. *Front Endocrinol* 3:154
- Davies P, Katzman R, Terry RD (1980) Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. *Nature* 288:279–280
- Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J (2006) Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. *Neurobiol Aging* 27:1658–1672
- Saito T, Iwata N, Tsubuki S, Takaki Y, Takano J, Huang SM, Sue-moto T, Higuchi M, Saido TC (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. *Nat Med* 11:434–439
- Iwata N, Tsubuki S, Takaki Y, Shiratani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. *Science* 292:1550–1552
- Sandoval KE, Witt KA, Crider AM, Kontoyianni M (2013) Somatostatin receptor-4 agonists as candidates for treatment of Alzheimer's disease. In: Atta-ur-Rahman Choudhary MI (ed) *Frontiers in drug design and discovery*. Bentham Science, Sharjah
- Viollet C, Lepousez G, Loudes C, Videau C, Simon A, Epelbaum J (2008) Somatostatinergic systems in brain: networks and functions. *Mol Cell Endocrinol* 286:75–87
- Moller LN, Stidsen CE, Hartmann B, Holst JJ (2003) Somatostatin receptors. *Biochem Biophys Acta* 1616:1–84
- Bruno JF, Xu Y, Song J, Berelowitz M (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. *Endocrinology* 133:2561–2567
- Harrington KA, Schindler M, Humphrey PP, Emson PC (1995) Expression of messenger RNA for somatostatin receptor subtype 4 in adult rat brain. *Neurosci Lett* 188:17–20
- Selmer IS, Schindler M, Humphrey PP, Emson PC (2000) Immunohistochemical localization of the somatostatin sst(4) receptor in rat brain. *Neuroscience* 98:523–533
- Selmer IS, Schindler M, Humphrey PP, Waldvogel HJ, Faull RL, Emson PC (2000) First localisation of somatostatin sst(4) receptor protein in selected human brain areas: an immunohistochemical study. *Brain Res Mol Brain Res* 82:114–125
- Sandoval KE, Farr SA, Banks WA, Crider AM, Morley JE, Witt KA (2012) Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular Abeta(1-)(4)(2) trimers. *Eur J Pharmacol* 683:116–124
- Sandoval KE, Farr SA, Banks WA, Crider AM, Morley JE, Witt KA (2013) Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Abeta oligomers via a metalloproteinase-dependent mechanism. *Brain Res* 1520:145–156
- Fleisher-Berkovich S, Filipovich-Rimon T, Ben-Shmuel S, Huls-mann C, Kummer MP, Heneka MT (2010) Distinct modulation of microglial amyloid beta phagocytosis and migration by neuro-peptides (i). *J Neuroinflamm* 7:61
- Tundo G, Ciaccio C, Sbardella D, Boraso M, Viviani B, Coletta M, Marini S (2012) Somatostatin modulates

- insulin-degrading-enzyme metabolism: implications for the regulation of microglia activity in AD. *PLoS ONE* 7:e34376
22. Ankersen M, Crider AM, Liu S, Ho B, Andersen HS, Stidsen CE (1998) Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity. *J Am Chem Soc* 120:1368–1373
 23. Caruso D, Barron AM, Brown MA, Abbiati F, Carrero P, Pike CJ, Garcia-Segura LM, Melcangi RC (2013) Age-related changes in neuroactive steroid levels in 3xTg-AD mice. *Neurobiol Aging* 34:1080–1089
 24. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron* 39:409–421
 25. Billings LM, Oddo S, Green KN, McLaugh JL, LaFerla FM (2005) Intraneuronal A β causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron* 45:675–688
 26. Rydbirk R, Folke J, Winge K, Aznar S, Pakkenberg B, Brudek T (2016) Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases. *Sci Rep* 6:37116
 27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 25:402–408
 28. Yuan JS, Reed A, Chen F, Stewart CN Jr (2006) Statistical analysis of real-time PCR data. *BMC Bioinform* 7:85
 29. Hukovic N, Panetta R, Kumar U, Patel YC (1996) Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. *Endocrinology* 137:4046–4049
 30. Gastambide F, Lepousez G, Viollet C, Loudes C, Epelbaum J, Guillou JL (2010) Cooperation between hippocampal somatostatin receptor subtypes 4 and 2: functional relevance in interactive memory systems. *Hippocampus* 20:745–757
 31. Somvanshi RK, Billova S, Kharmate G, Rajput PS, Kumar U (2009) C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. *Cell Signal* 21:1396–1414
 32. Zou Y, Tan H, Zhao Y, Zhou Y, Cao L (2019) Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. *Oncol Lett* 17:1723–1731
 33. Nalivaeva NN, Belyaev ND, Kerridge C, Turner AJ (2014) Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. *Front Aging Neurosci* 6:235
 34. Saido T, Leissring MA (2012) Proteolytic degradation of amyloid beta-protein. *Cold Spring Harbor Perspect Med* 2:a006379
 35. Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC (2002) A β -degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with A β pathology. *Neurosci Res* 43:39–56
 36. Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. *Neurosci Lett* 350:113–116
 37. Takaki Y, Iwata N, Tsubuki S, Taniguchi S, Toyoshima S, Lu B, Gerard NP, Gerard C, Lee HJ, Shirokani K, Saido TC (2000) Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. *J Biochem* 128:897–902
 38. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *J Neurosci* 20:1657–1665
 39. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *J Biol Chem* 273:32730–32738
 40. Stargardt A, Gillis J, Kamphuis W, Wiemhoefer A, Kooijman L, Raspe M, Benckhuijsen W, Drijfhout JW, Hol EM, Reits E (2013) Reduced amyloid-beta degradation in early Alzheimer's disease but not in the APP^{swE}PS1^{dE9} and 3xTg-AD mouse models. *Aging Cell* 12:499–507
 41. Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. *Neuroscience* 39:151–170
 42. Funalot B, Ouimet T, Claperton A, Fallet C, Delacourte A, Epelbaum J, Subkowski T, Leonard N, Codron V, David JP, Amouyel P, Schwartz JC, Helbecque N (2004) Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease. *Mol Psychiatry* 9(1122–1128):1059
 43. Arregui A, Perry EK, Rossor M, Tomlinson BE (1982) Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. *J Neurochem* 38:1490–1492
 44. Helyes Z, Pinter E, Nemeth J, Sandor K, Elekes K, Szabo A, Pozsgai G, Keszthelyi D, Kereskai L, Engstrom M, Wurster S, Szolcsanyi J (2006) Effects of the somatostatin receptor subtype 4 selective agonist J-2156 on sensory neuropeptide release and inflammatory reactions in rodents. *Br J Pharmacol* 149:405–415
 45. Helyes Z, Pinter E, Sandor K, Elekes K, Banvolgyi A, Keszthelyi D, Szoke E, Toth DM, Sandor Z, Kereskai L, Pozsgai G, Allen JP, Emson PC, Markovics A, Szolcsanyi J (2009) Impaired defense mechanism against inflammation, hyperalgesia, and airway hyper-reactivity in somatostatin 4 receptor gene-deleted mice. *Proc Natl Acad Sci USA* 106:13088–13093
 46. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer's disease. *Lancet Neurol* 14:388–405
 47. Jiang T, Yu JT, Hu N, Tan MS, Zhu XC, Tan L (2014) CD33 in Alzheimer's disease. *Mol Neurobiol* 49:529–535
 48. Griciu A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* 78:631–643
 49. Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR (2001) Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. *NeuroReport* 12:1151–1154
 50. Frenkel D, Wilkinson K, Zhao L, Hickman SE, Means TK, Puckett L, Farfara D, Kingery ND, Weiner HL, El Khoury J (2013) Scara1 deficiency impairs clearance of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. *Nat Commun* 4:2030
 51. Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. *J Neuropathol Exp Neurol* 69:155–167
 52. Gsell W, Conrad R, Hicketier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H et al (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. *J Neurochem* 64:1216–1223
 53. Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, Vihalemm T, Kairane C, Zilmer M (2001) The cerebrocortical areas in normal brain aging and in Alzheimer's disease:

- noticeable differences in the lipid peroxidation level and in anti-oxidant defense. *Neurochem Res* 26:353–361
54. Fanelli F, Sepe S, D'Amelio M, Bernardi C, Cristiano L, Cimini A, Cecconi F, Ceru MP, Moreno S (2013) Age-dependent roles of peroxisomes in the hippocampus of a transgenic mouse model of Alzheimer's disease. *Molecular neurodegeneration* 8:8
55. Franca MB, Lima KC, Eleutherio EC (2017) Oxidative stress and amyloid toxicity: insights from yeast. *J Cell Biochem* 118:1442–1452
56. Morita M, Kurochkin IV, Motojima K, Goto S, Takano T, Okamura S, Sato R, Yokota S, Imanaka T (2000) Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins. *Cell Struct Funct* 25:309–315
57. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. *Neurobiol Aging* 26:645–654
58. Wang DS, Iwata N, Hama E, Saido TC, Dickson DW (2003) Oxidized neprilysin in aging and Alzheimer's disease brains. *Biochem Biophys Res Commun* 310:236–241
59. Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castano JP, Wester HJ, Culler M, Melmed S, Schulz S (2018) International union of basic and clinical pharmacology. CV. somatostatin receptors: structure, function, ligands, and new nomenclature. *Pharmacol Rev* 70:763–835

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.